钠-葡萄糖协同转运蛋白2抑制剂在2型糖尿病合并急性肾病患者中的应用
这项基于TriNetX全球医疗数据的队列研究纳入230 366例2型糖尿病合并急性肾病患者,其中2.3%为SGLT-2i使用者,中位随访2.3年。倾向性评分匹配后,SGLT-2i使用与全因死亡(AHR 0.69,95%CI 0.62-0.77)、主要不良肾脏事件(AHR 0.62,95%CI 0.56-0.69)和主要不良心血管事件(AHR 0.75,95%CI 0.65-0.88)风险显著降低相关。外部验证使用1233例SGLT-2i使用者的多中心队列数据证实了观察到的有益结局。作者认为这些发现强调SGLT-2i在急性肾损伤后护理中的重要性。
要点
- 在2型糖尿病合并急性肾病患者中,SGLT-2i使用与全因死亡风险显著降低相关(AHR 0.69,95%CI 0.62-0.77)。
- SGLT-2i使用与主要不良肾脏事件风险显著降低相关(AHR 0.62,95%CI 0.56-0.69)。
- SGLT-2i使用与主要不良心血管事件风险显著降低相关(AHR 0.75,95%CI 0.65-0.88)。
- 倾向性评分匹配后,SGLT-2i使用者与非使用者的死亡、MAKEs和MACEs发生率绝对差异分别为9.7%、11.5%和12.3%。
- 即使在没有高血压、晚期慢性肾脏病或未接受其他降糖药的患者中,SGLT-2i相关的风险降低仍然显著。
适用人群与场景
- 2型糖尿病合并急性肾病患者,来自TriNetX全球医疗数据库,2002年9月30日至2022年9月30日。
- 平均(SD)年龄67.1(16.4)岁,51.8%为男性,48.2%为女性。
研究设计与关键结果
- 研究类型为队列研究,使用TriNetX全球医疗数据,纳入230 366例2型糖尿病合并急性肾病患者,其中5319例(2.3%)为SGLT-2i使用者。
- 中位随访时间2.3年(IQR 1.2-3.5年),最长随访5年或至结局发生或死亡。
- 非使用者中,死亡发生率为18.7%,主要不良肾脏事件发生率为21.0%,主要不良心血管事件发生率为25.8%。
- 倾向性评分匹配后,SGLT-2i使用者与非使用者死亡、MAKEs和MACEs发生率的绝对差异分别为9.7%、11.5%和12.3%。
- 基于治疗人群,SGLT-2i使用与非使用相比,全因死亡风险显著降低(AHR 0.69,95%CI 0.62-0.77),MAKEs风险显著降低(AHR 0.62,95%CI 0.56-0.69),MACEs风险显著降低(AHR 0.75,95%CI 0.65-0.88)。
- 外部验证使用1233例SGLT-2i使用者的多中心队列数据,证实了观察到的有益结局。
- 风险降低在无高血压、晚期慢性肾脏病以及未接受其他降糖药的患者中仍然显著。
证据类型、等级与局限
- 证据类型:队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,这些发现强调SGLT-2i在急性肾损伤后护理中的重要性。
- 作者认为,这些发现强调SGLT-2i在管理急性肾病和减轻主要心血管和肾脏疾病风险方面的潜在益处。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Sodium-glucose cotransport protein 2 inhibitors (SGLT-2is) have demonstrated associations with positive kidney-related and cardiovascular outcomes in patients with type 2 diabetes. However, the association of SGLT-2is with outcomes among patients with type 2 diabetes and acute kidney disease (AKD) remains unclear.
OBJECTIVE: To examine the long-term associations of SGLT-2is with mortality, major adverse kidney events (MAKEs), and major adverse cardiovascular events (MACEs) in patients with type 2 diabetes and AKD.
DESIGN, SETTING, AND PARTICIPANTS: This cohort study used global health care data (the TriNetX database) spanning from September 30, 2002, to September 30, 2022. Propensity score matching was used to select a cohort of patients, and follow-up was conducted with a maximum duration of 5 years (completed on September 30, 2022) or until the occurrence of an outcome or death.
INTERVENTION: The use of SGLT-2is.
MAIN OUTCOMES AND MEASURES: The primary outcomes measured were mortality, MAKEs, and MACEs. Adjusted hazard ratios (AHR) with 95% CIs were calculated to compare the risks between SGLT-2i users and nonusers, representing the mean treatment effect among the treated patients.
RESULTS: A total of 230 366 patients with AKD (mean [SD] age, 67.1 [16.4] years; 51.8% men and 48.2% women) were enrolled in the study, which had a median follow-up duration of 2.3 (IQR, 1.2-3.5) years. Among these, 5319 individuals (2.3%) were identified as SGLT-2i users. Among nonusers, the incidence of mortality was 18.7%, the incidence of MAKEs was 21.0%, and the incidence of MACEs was 25.8%. After propensity score matching, the absolute differences between SGLT-2i users and nonusers for incidence of mortality, MAKEs, and MACEs were 9.7%, 11.5%, and 12.3%, respectively. Based on the treated population, SGLT-2i use was associated with a significantly lower risk of mortality (AHR, 0.69 [95% CI, 0.62-0.77]), MAKEs (AHR, 0.62 [95% CI, 0.56-0.69]), and MACEs (AHR, 0.75 [95% CI, 0.65-0.88]) compared with nonuse. External validation using a multicenter cohort data set of 1233 patients with AKD patients who were SGLT-2i users confirmed the observed beneficial outcomes. Notably, the risk reduction associated with SGLT-2is remained significant even among patients without hypertension, those with advanced chronic kidney disease, and those not receiving other hypoglycemic agents.
CONCLUSIONS AND RELEVANCE: In this cohort study of patients with type 2 diabetes and AKD, administration of SGLT-2is was associated with a significant reduction in all-cause mortality, MAKEs, and MACEs when compared with nonuse, underscoring the importance of SGLT-2is in care after acute kidney injury. These findings emphasize the potential benefits of SGLT-2is in managing AKD and mitigating the risks of major cardiovascular and kidney diseases.
参考来源
- Pan HC, Chen JY, Chen HY, et al. Sodium-Glucose Cotransport Protein 2 Inhibitors in Patients With Type 2 Diabetes and Acute Kidney Disease. JAMA Netw Open. 2024. PMID: 38170522. doi:10.1001/jamanetworkopen.2023.50050
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。